Can­cer spe­cial­ist Hi­ber­Cell snaps up an­a­lyt­ics, com­pu­ta­tion­al tools in all-stock buy­out; Prax­is re­veals new per­i­menopausal de­pres­sion da­ta

In a slight­ly un­con­ven­tion­al deal, New York-based Hi­ber­Cell is lever­ag­ing a chunk of its stock — still pri­vate­ly owned — to buy out Ge­nu­ity Sci­ence and its suite of tools for ge­nomics and mul­ti-om­ic an­a­lyt­ics, as well as an AI and ma­chine learn­ing plat­form.

The goal, ac­cord­ing to CEO Alan Rig­by, is to fur­ther Hi­ber­Cell’s un­der­stand­ing of the adap­tive stress phe­no­type and its role in can­cer pro­gres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER